Immunoprecise Antibodies Ltd (IPA) — Long-term Investment Intensity
Immunoprecise Antibodies Ltd (IPA) has a Long-term Investment Intensity of 0.0% as of July 2023. Long-term investments of $27.00K represent 0.0% of total assets of $79.94 Million. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. See net assets of Immunoprecise Antibodies Ltd for net asset value and shareholders' equity analysis.
LT Investment Intensity
Long-term Investments
Total Assets
Country
Immunoprecise Antibodies Ltd Long-term Investment Intensity (2018–2023)
This chart shows how Immunoprecise Antibodies Ltd's Long-term Investment Intensity has evolved across 6 annual periods from 2018 to 2023. As of July 2023, the intensity stands at 0.0%, reflecting long-term investments of $27.00K against total assets of $79.94 Million USD. Also explore Immunoprecise Antibodies Ltd (IPA) total assets for the complete picture of this company's asset base.
Annual Long-term Investment Intensity for Immunoprecise Antibodies Ltd (2018–2023)
The table below presents the year-by-year Long-term Investment Intensity for Immunoprecise Antibodies Ltd from 2018 to 2023, covering 6 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. For market capitalisation and broader financial context, see IPA company net worth.
| Year | LT Investment Intensity | LT Investments (USD) | Total Assets | Change (pp) |
|---|---|---|---|---|
| 2023 | 0.1% | $115.00K | $77.81 Million | ▼ 0.0 pp |
| 2022 | 0.2% | $142.00K | $93.49 Million | ▼ 0.0 pp |
| 2021 | 0.2% | $111.00K | $66.96 Million | ▼ -0.3 pp |
| 2020 | 0.4% | $118.90K | $27.26 Million | ▲ +0.1 pp |
| 2019 | 0.3% | $90.40K | $28.35 Million | ▼ 0.0 pp |
| 2018 | 0.4% | $90.40K | $24.58 Million | — |